Literature DB >> 19064719

Cathepsins B and L differentially regulate amyloid precursor protein processing.

Donna M Klein1, Kevin M Felsenstein, Douglas E Brenneman.   

Abstract

Previous studies have shown that cathepsins control amyloid beta (Abeta) levels in chromaffin cells via a regulated secretory pathway. In the present study, this concept was extended to investigations in primary hippocampal neurons to test whether Abeta release was coregulated by cathepsins and electrical activity, proposed components of a regulated secretory pathway. Inhibition of cathepsin B (catB) activity with CA074Me or attenuation of catB expression through small interfering RNA produced decreases in Abeta release, similar to levels produced with suppression of beta-site APP-cleaving enzyme 1 (BACE1) expression. To test whether the catB-dependent release of Abeta was linked to ongoing electrical activity, neurons were treated with tetrodotoxin (TTX) and CA074Me. These comparisons demonstrated no additivity between decreases in Abeta release produced by TTX and CA074Me. In contrast, pharmacological inhibition of cathepsin L (catL) selectively elevated Abeta42 levels but not Abeta40 or total Abeta. Mechanistic studies measuring C-terminal fragments of amyloid precursor protein (APP) suggested that catL elevated alpha-secretase activity, thereby suppressing Abeta42 levels. The mechanism of catB-mediated regulation of Abeta release remains unclear but may involve elevation of beta-secretase. In summary, these studies provide evidence for a significant alternative pathway for APP processing that involves catB and activity-dependent release of Abeta in a regulated secretory pathway for primary neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19064719     DOI: 10.1124/jpet.108.147082

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.

Authors:  Vivian Hook; Gregory Hook; Mark Kindy
Journal:  Biol Chem       Date:  2010-08       Impact factor: 3.915

Review 2.  An overview of APP processing enzymes and products.

Authors:  Vivian W Chow; Mark P Mattson; Philip C Wong; Marc Gleichmann
Journal:  Neuromolecular Med       Date:  2010-03       Impact factor: 3.843

3.  Hyperbaric Oxygen Prevents Cognitive Impairments in Mice Induced by D-Galactose by Improving Cholinergic and Anti-apoptotic Functions.

Authors:  Chunxia Chen; Luying Huang; Zhihuan Nong; Yaoxuan Li; Wan Chen; Jianping Huang; Xiaorong Pan; Guangwei Wu; Yingzhong Lin
Journal:  Neurochem Res       Date:  2017-01-11       Impact factor: 3.996

4.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 5.  Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease.

Authors:  Vivian Hook; Lydiane Funkelstein; Jill Wegrzyn; Steven Bark; Mark Kindy; Gregory Hook
Journal:  Biochim Biophys Acta       Date:  2011-09-08

6.  Iron dysregulates APP processing accompanying with sAPPα cellular retention and β-secretase inhibition in rat cortical neurons.

Authors:  Yu-Ting Chen; Wu-Yan Chen; Xiao-Tian Huang; Ye-Chun Xu; Hai-Yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-08-24       Impact factor: 6.150

7.  Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters.

Authors:  Thomas Toneff; Lydiane Funkelstein; Charles Mosier; Armen Abagyan; Michael Ziegler; Vivian Hook
Journal:  Peptides       Date:  2013-06-06       Impact factor: 3.750

8.  Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence.

Authors:  Mark S Kindy; Jin Yu; Hong Zhu; Salim S El-Amouri; Vivian Hook; Gregory R Hook
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

9.  Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.

Authors:  Gregory Hook; Jin Yu; Thomas Toneff; Mark Kindy; Vivian Hook
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

10.  Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein.

Authors:  Vivian Y H Hook; Mark Kindy; Thomas Reinheckel; Christoph Peters; Gregory Hook
Journal:  Biochem Biophys Res Commun       Date:  2009-06-06       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.